Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Citrate Dose Regimens in NDD-CKD with Iron-Deficiency Anemia
NCT03236246Phase 4Completed
- Sponsor
- Keryx Biopharmaceuticals, Inc.
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric citrate in iron deficiency anemia (IDA) (2 arms), sponsored by Keryx Biopharmaceuticals, Inc. Primary endpoint: Change From Baseline in Hemoglobin at Week 24. Started Aug 2017; status: completed.
02
Drugs
ferric citrate
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03236246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236246.